Patent ID: 11866466
Assignee: BLAZE BIOSCIENCE, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A  G | IPC A  C

Claim 12:
13. A method of treating cancer in a subject in need thereof, the method comprising:
administering to the subject a composition comprising a peptide-immuno-oncology agent complex, the peptide-immuno-oncology agent complex comprising a peptide complexed with an immuno-oncology agent, wherein the peptide of the peptide-immuno-oncology agent complex comprises:
at least 4 cysteine residues, and
a plurality of disulfide bridges formed between the cysteine residues;
wherein the immuno-oncology agent comprises an IL-15 agent, and
wherein the peptide-immuno-oncology agent complex comprises:
a) SEQ ID NO: 1330;
b) SEQ ID NO: 1340; or
c) any one of SEQ ID NO: 1317, SEQ ID NO: 1328, SEQ ID NO: 1435, SEQ ID NO: 1437, or SEQ ID NO: 1441; and
delivering the immuno-oncology agent to the cancer, wherein the cancer is a solid tumor, a metastatic cancer lesion, a central nervous system cancer, glioma, glioblastoma, a brain cancer, a brain tumor, breast cancer, ovarian cancer, melanoma, sarcoma, basal cell carcinoma, squamous cell carcinoma, skin cancer, lung cancer, colon cancer, colorectal cancer, pancreatic cancer, prostate cancer, bladder cancer, or any combination thereof, thereby treating the cancer.